Moderna is trading at $257.98, up 12.93%, with its move linked to early data for its experimental mRNA-2808 multiple myeloma therapy.
- Four confirmed responses were observed among 11 evaluable patients, and all three encoded T-cell engagers were detected.
- Moderna said the data would be presented at the December ASH meeting.
- Biotech was up about 2% amid optimism following the U.S. midterm results; no reliable volume figure was provided.